Similar articles

• Phase II study of everolimus in metastatic urothelial cancer.

  Milowsky MI, Iyer G, Regazzi AM, Al-Ahmadie H, Gerst SR, Ostrovnaya I, Gellert LL, Kaplan R, Garcia-Grossman IR, Pendse D, Balar AV, Flaherty AM, Trout A, Solit DB, Bajorin DF. Milowsky MI, et al. BJU Int. 2013 Aug;112(4):462-70. doi: 10.1111/j.1464-410X.2012.11720.x. Epub 2013 Apr 3. BJU Int. 2013. PMID: 23551593 Free PMC article. Clinical Trial.
• Long-term response in advanced bladder cancer involving the use of temsirolimus and vinflunine after platin resistance.

  Gerullis H, Ecke TH, Janusch B, Arndt C, Heidari M, Oniani J, Otto T. Gerullis H, et al. Anticancer Drugs. 2011 Oct;22(9):940-3. doi: 10.1097/CAD.0b013e328347a86a. Anticancer Drugs. 2011. PMID: 21642839
• Management of disseminated disease in the patient with bladder cancer.

  Perry JJ, Muss HB. Perry JJ, et al. Urol Clin North Am. 1994 Nov;21(4):661-72. Urol Clin North Am. 1994. PMID: 7974898 Review.
• Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers.

  Seront E, Rottey S, Sautois B, Kerger J, D'Hondt LA, Verschaeve V, Canon JL, Dopchie C, Vandenbulcke JM, Whenham N, Goeminne JC, Clausse M, Verhoeven D, Glorieux P, Branders S, Dupont P, Schoonjans J, Feron O, Machiels JP. Seront E, et al. Ann Oncol. 2012 Oct;23(10):2663-2670. doi: 10.1093/annonc/mds057. Epub 2012 Apr 3. Ann Oncol. 2012. PMID: 22473592 Clinical Trial.
• Second-line systemic therapy for metastatic urothelial carcinoma of the bladder.

  Ortmann CA, Mazhar D. Ortmann CA, et al. Future Oncol. 2013 Nov;9(11):1637-51. doi: 10.2217/fon.13.139. Future Oncol. 2013. PMID: 24156324 Review.